Gain insight from Dr Colbert into how patients with IgAN typically present in the clinic. Learn more about the IgAN patient journey: References: Read More
Learn from Dr Lerma about the MEST-C score and how it is used to assess the risk of IgAN progression. Learn more about the evolving clinical approach to IgAN: References: Read More
Gain insight into target proteinuria thresholds and their relevance in IgAN management from Dr Colbert. Learn more about IgAN pathophysiology: References: Read More
Discover with Dr Lerma how APRIL acts as a key driver of the 4-hit process in IgAN pathogenesis. Learn more about IgAN pathophsyiology: References: 1. Chacko B, et al. ASN… Read More
Learn about the current strategies for the management of IgAN and the ongoing need for therapies that target the underlying causes of IgAN. Hear more from our experts: References: Read More
Explore how early detection and diagnosis of IgAN can support timely treatment and help reduce the risk of disease progression. Hear more from our experts: Reference: Read More
Explore the role of APRIL in B-cell development and IgAN pathogenesis, and learn how a better understanding of IgAN pathophysiology allows for a more targeted management approach. Hear more from… Read More
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the kidney health community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.